

AMENDMENTS TO THE CLAIMS

1. (Cancelled)

2. (Original) A method of treating an inflammatory disease or condition reducing inflammation in a mammal, comprising selecting an LXR agonist that exhibits a greater effect on expression of an inflammatory gene than on expression of a lipid metabolism gene, and administering to the mammal an a-therapeutically effective amount of said an LXR agonist, wherein said therapeutically effective amount sufficient to treat the disease or condition, of said LXR-agonist exhibits a relatively greater effect on expression of an inflammatory gene than on expression of a lipid metabolism gene, such that inflammation is reduced without a significant effect on lipid metabolism.

3. (Cancelled)

4. (Cancelled)

5. (Currently amended) The method of Claim 2[[4]], wherein the inflammatory disease or condition is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, bursitis, Sjogren's syndrome, psoriasis, psoriatic arthritis, neuralgia, synoviitis, glomerulonephritis, vasculitis, sarcoidosis, atherosclerosis, asthma, inflammatory bowel disease, inflammations that occur as sequelae to influenza, the common cold and other viral infections, gout, contact dermatitis, low back and neck pain, dysmenorrhea, headache, toothache, sprains, strains, myositis, burns, injuries, and pain and inflammation that follow surgical and dental procedures in a patient.

6.-13. (Cancelled)

14. (Currently amended) A The method of claim 2for treating an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of an LXR-agonist, wherein said inflammatory disease or condition is macrophage-dependentdependent.

15. (Currently amended) The method of Claim 14, wherein said inflammatory disease or condition is atherosclerosis, rheumatoid arthritis, or glomerulonephritis.

16. (Cancelled)

Application No.: 10/755,720
Filing Date: January 12, 2004

17. (Currently amended) The method of ~~any one of~~ Claim[[s]] 1, 2, 3, 4, 5, 6, 7, 9,
11-13, 14, or 16, wherein said LXR agonist is GW3965 or T0901317.

18.-20. (Canceled)